Total Payments
$6,672
2024 Payments
$482.47
Companies
17
Transactions
111
Medicare Patients
542
Medicare Billing
$74,922
Payment Breakdown by Category
Food & Beverage$5,735 (86.0%)
Consulting$904.00 (13.5%)
Education$33.11 (0.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,735 | 106 | 86.0% |
| Consulting Fee | $904.00 | 1 | 13.5% |
| Education | $33.11 | 4 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,400 | 37 | $0 (2024) |
| Novo Nordisk Inc | $1,342 | 17 | $0 (2023) |
| GE HEALTHCARE | $904.00 | 1 | $0 (2023) |
| Lilly USA, LLC | $692.71 | 24 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $241.32 | 4 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $209.58 | 2 | $0 (2018) |
| Bayer Healthcare Pharmaceuticals Inc. | $183.99 | 4 | $0 (2024) |
| GlaxoSmithKline, LLC. | $138.47 | 2 | $0 (2017) |
| ARBOR PHARMACEUTICALS, INC. | $135.98 | 9 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $133.73 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $482.47 | 6 | AstraZeneca Pharmaceuticals LP ($459.68) |
| 2023 | $1,345 | 8 | GE HEALTHCARE ($904.00) |
| 2022 | $234.82 | 7 | Novo Nordisk Inc ($152.41) |
| 2021 | $675.75 | 9 | Novo Nordisk Inc ($509.02) |
| 2020 | $700.36 | 13 | AstraZeneca Pharmaceuticals LP ($400.06) |
| 2019 | $679.41 | 14 | Lilly USA, LLC ($223.68) |
| 2018 | $766.70 | 16 | AstraZeneca Pharmaceuticals LP ($240.98) |
| 2017 | $1,788 | 38 | AstraZeneca Pharmaceuticals LP ($842.31) |
All Payment Transactions
111 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $101.33 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $97.96 | General |
| Category: Respiratory | ||||||
| 04/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Cardio-renal | ||||||
| 03/27/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $119.23 | General |
| Category: Respiratory | ||||||
| 03/14/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $120.37 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/12/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/03/2023 | GE HEALTHCARE | — | Consulting Fee | Cash or cash equivalent | $904.00 | General |
| 11/07/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Respiratory | ||||||
| 06/22/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $120.36 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/09/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: Obesity | ||||||
| 04/27/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $122.61 | General |
| Category: Diabetes | ||||||
| 03/14/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/23/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $122.87 | General |
| Category: Cardio-renal | ||||||
| 02/14/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: Cardio-renal | ||||||
| 10/27/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.33 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/30/2022 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: Diabetes | ||||||
| 07/19/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.39 | General |
| Category: Cardio-renal | ||||||
| 06/28/2022 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: Diabetes | ||||||
| 06/23/2022 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $124.95 | General |
| Category: Diabetes | ||||||
| 03/03/2022 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: Obesity | ||||||
| 01/20/2022 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $10.17 | General |
| Category: Obesity | ||||||
| 12/02/2021 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $105.23 | General |
| Category: Diabetes | ||||||
| 08/12/2021 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $118.85 | General |
| Category: Diabetes | ||||||
| 07/29/2021 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $121.41 | General |
| Category: Diabetes | ||||||
| 06/30/2021 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $124.59 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 103 | 165 | $27,240 | $13,155 |
| 2022 | 5 | 110 | 180 | $27,670 | $13,592 |
| 2021 | 6 | 157 | 269 | $38,710 | $21,041 |
| 2020 | 5 | 172 | 359 | $52,740 | $27,134 |
Total Patients
542
Total Services
973
Medicare Billing
$74,922
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 81 | $18,620 | $7,950 | 42.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 21 | 21 | $5,230 | $2,801 | 53.6% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 20 | 20 | $2,100 | $1,516 | 72.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 22 | 22 | $1,080 | $711.04 | 65.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 15 | 21 | $210.00 | $176.40 | 84.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 34 | 96 | $21,120 | $9,371 | 44.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 17 | 17 | $4,190 | $2,324 | 55.5% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 18 | 18 | $1,440 | $1,265 | 87.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 18 | 18 | $610.00 | $540.61 | 88.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 23 | 31 | $310.00 | $91.89 | 29.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 46 | 140 | $28,020 | $14,352 | 51.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 24 | 24 | $5,020 | $3,364 | 67.0% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 22 | 22 | $1,750 | $1,461 | 83.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 13 | 19 | $2,750 | $1,270 | 46.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 28 | 28 | $810.00 | $486.18 | 60.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 24 | 36 | $360.00 | $108.00 | 30.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 53 | 236 | $42,390 | $20,617 | 48.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 33 | 33 | $6,340 | $4,038 | 63.7% |
| 90662 | Vaccine for influenza for injection into muscle | Office | 2020 | 30 | 30 | $2,500 | $1,829 | 73.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 32 | 32 | $1,230 | $565.76 | 46.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 24 | 28 | $280.00 | $83.70 | 29.9% |
About Dr. Bahir Mansur, MD
Dr. Bahir Mansur, MD is a Family Medicine healthcare provider based in Forest Park, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487756474.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bahir Mansur, MD has received a total of $6,672 in payments from pharmaceutical and medical device companies, with $482.47 received in 2024. These payments were reported across 111 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($5,735).
As a Medicare-enrolled provider, Mansur has provided services to 542 Medicare beneficiaries, totaling 973 services with total Medicare billing of $74,922. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Forest Park, IL
- Active Since 09/01/2006
- Last Updated 07/08/2007
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1487756474
Products in Payments
- FARXIGA (Drug) $1,736
- RYBELSUS (Drug) $469.80
- TRULICITY (Drug) $379.44
- Tresiba (Drug) $313.47
- Ozempic (Drug) $266.12
- JARDIANCE (Drug) $264.65
- ENTRESTO (Drug) $241.32
- BEVESPI AEROSPHERE (Drug) $228.82
- Xultophy 100/3.6 (Drug) $220.47
- BREZTRI (Drug) $214.89
- Kerendia (Drug) $183.99
- XIFAXAN (Drug) $139.53
- AIRSUPRA (Drug) $136.84
- MOUNJARO (Drug) $122.61
- INCRUSE (Drug) $115.04
- ELIQUIS (Drug) $112.25
- LUCEMYRA (Drug) $84.59
- ATTUNE (Device) $78.84
- Edarbyclor (Drug) $74.55
- SYMBICORT (Drug) $71.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Forest Park
Faith Andrews, Md, MD
Family Medicine — Payments: $17,146
Family Medicine $17,146
Dr. Angela Evans, Do, DO
Family Medicine — Payments: $2,665
Family Medicine $2,665
Miriam Gwathney, Do, DO
Family Medicine — Payments: $22.04
Family Medicine $22.04
Mr. Shiann Lin, Md, MD
Family Medicine
Family Medicine